Brief
Enveda Raises $311M to Advance AI-Discovered Nature-Based Drugs
AI biotech startup Enveda raises $311 million to advance nature-derived drug candidates into human clinical trials.
8 articles
AI biotech startup Enveda raises $311 million to advance nature-derived drug candidates into human clinical trials.
Anthropic confirms it operates a wet biology lab in the Bay Area where AI models support physical experiments focused on fundamental biology research.
Outer Biosciences uses living human skin and machine learning to discover new cosmetic ingredients, keeping tissue viable for up to four weeks in the lab.
OpenAI researcher Miles Wang is reportedly leaving the company to launch an AI drug discovery startup, with funding talks valuing the venture at about $2 billion.
Anthropic introduces Claude Science, a research workbench that helps scientists manage workflows, analyse data, and accelerate discoveries using existing Claude AI models.
Imperagen has raised £5 million to combine quantum physics and artificial intelligence for enzyme engineering, accelerating biotechnology research and industrial innovation.
Anthropic is reportedly acquiring biotech startup Coefficient Bio for $400 million, marking a major move into AI-driven biology and life sciences.
AI-driven drug discovery startup Converge Bio has raised a $25 million Series A round led by Bessemer Venture Partners to accelerate pharmaceutical research using generative models trained…
Written by the reporters who cover each beat. Unsubscribe in one click.